This summary provides more information on the future work that VALUE-Dx will carry out in the coming years across 20 European countries on community-acquired acute respiratory tract infections (CA-ARTI). This includes details the three winter seasons from 2019 to 2022:
- 1st winter season of 2019-2020 – a web-based point prevalence audit survey (PPAS);
- 2nd winter season of 2020-2021 – platform randomised controlled trial of point of care diagnostics (PRUDENCE trial);
- 3rd winter season of 2021-2022 – PRUDENCE trial.
Whilst the web-based PPAS will record information about patients seeking healthcare for CA-ARTI, the PRUDENCE trial will evaluate clinical algorithms that incorporate a point of care test for CA-ARTI.
Furthermore, this summary provides an update on the activities that have already begun during the first year of VALUE-Dx.
